MiCo BioMed USA

Executive Summary

MiCo BioMed USA is a San Diego-based biotechnology company founded in 2018, specializing in microfluidic immunoassay platforms. Its proprietary Optimiser™ technology enhances the sensitivity, throughput, and cost-efficiency of diagnostic testing. The company’s product portfolio includes the TROVA™ point-of-care system for rapid, decentralized testing and the OptiMax™ series designed for STAT labs and high-throughput automation. By addressing the need for faster, more accurate diagnostics, MiCo BioMed positions itself to capture market share in the growing point-of-care and lab automation segments. The company has secured regulatory approval and is likely generating early revenue, though financial details remain undisclosed. With its innovative platform, MiCo BioMed USA could be an attractive partner for larger diagnostic firms seeking to expand their microfluidic capabilities.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for TROVA™ point-of-care system60% success
• Q4 2026Strategic partnership with a major diagnostics distributor50% success
• Q2 2026Launch of OptiMax™ series for high-throughput labs70% success